6IO Stock Chart & Stats
€5.85
-€0.05(-0.56%)
At close: 4:00 PM EST
€5.85
-€0.05(-0.56%)
Day’s Range― - ―
52-Week Range€4.50 - €7.65
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€153.12M
Enterprise Value€94.99M
Total Cash (Recent Filing)€111.47M
Total Debt (Recent Filing)€16.93M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Aug 12, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding27,074,516
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)0.95
Price to Sales (P/S)0.52
P/FCF Ratio-8.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.53Price Target Upside80.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.66
Revenue Forecast (FY)€317.72M
Bulls Say, Bears Say
Bulls Say
International Revenue GrowthSustained double-digit international growth reflects successful geographic expansion and deeper HME/tender relationships across Eastern Europe, Latin America and APAC. This diversifies revenue away from the U.S. and builds a more resilient, multi-market base that supports durable top-line momentum and scale.
Unit Volume Expansion / Installed Base Growth14% unit volume growth increases the installed base, which durably drives recurring accessory, service and replacement revenue. A larger installed base also compounds clinical data collection and customer relationships, improving long-term monetization and competitive position versus peers reliant on one-time sales.
Strong Liquidity And Low LeverageA cash-rich, zero-debt balance sheet provides meaningful runway to fund product launches, clinical programs and international expansion without near-term refinancing. This financial flexibility supports strategic investments and risk absorption as the company pursues sustained profitability and scale.
Bears Say
Ongoing Losses And Negative EBITDAPersistent GAAP losses and negative adjusted EBITDA indicate the business has not yet returned to sustained earnings power. Continued unprofitability constrains reinvestment, reduces margin of safety for investors, and requires either sustained cash reserves or operational improvements to reach durable positive cash generation.
Negative And Volatile Free Cash FlowConsistent negative free cash flow and volatile operating cash flow reduce self-funding capacity and increase dependence on cash reserves or capital markets. This weakens financial optionality and raises execution risk for commercial expansion and R&D over the next several quarters.
U.S. Sales And Rental Channel WeaknessA structural shift in the U.S. toward POCs is pressuring direct-to-consumer and rental channels, eroding recurring rental revenue and complicating unit economics. Slower U.S. placement and rental declines could persist for quarters, limiting near-term domestic revenue and margin recovery.
Inogen News
6IO FAQ
What was Inogen Inc’s price range in the past 12 months?
Inogen Inc lowest stock price was €4.50 and its highest was €7.65 in the past 12 months.
What is Inogen Inc’s market cap?
Inogen Inc’s market cap is €153.12M.
When is Inogen Inc’s upcoming earnings report date?
Inogen Inc’s upcoming earnings report date is Aug 12, 2026 which is in 42 days.
How were Inogen Inc’s earnings last quarter?
Inogen Inc released its earnings results on May 07, 2026. The company reported -€0.263 earnings per share for the quarter, missing the consensus estimate of -€0.248 by -€0.015.
Is Inogen Inc overvalued?
According to Wall Street analysts Inogen Inc’s price is currently Undervalued.
Does Inogen Inc pay dividends?
Inogen Inc does not currently pay dividends.
What is Inogen Inc’s EPS estimate?
Inogen Inc’s EPS estimate is -0.13.
How many shares outstanding does Inogen Inc have?
Inogen Inc has 27,074,516 shares outstanding.
What happened to Inogen Inc’s price movement after its last earnings report?
Inogen Inc reported an EPS of -€0.263 in its last earnings report, missing expectations of -€0.248. Following the earnings report the stock price went up 0.833%.
Which hedge fund is a major shareholder of Inogen Inc?
Currently, no hedge funds are holding shares in DE:6IO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inogen Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€10.53 (80.04% Upside)
€10.53 (80.04% Upside)
Blogger Sentiment
Bullish
DE:6IO Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.54%
12-Months-Change
Fundamentals
Return on Equity
-12.90%
Trailing 12-Months
Asset Growth
-7.29%
Trailing 12-Months
Company Description
Inogen Inc
Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment. These cutting-edge devices are engineered to provide continuous oxygen support for patients managing persistent respiratory conditions. The company's diverse product range features the popular portable Inogen One, which efficiently draws oxygen from the surrounding atmosphere to offer an independent supply, alongside stationary Inogen At Home concentrators, Tidal Assist Ventilators, and various associated accessories. Inogen serves a broad clientele, including individual patients, medical professionals, and insurance providers, both domestically in the United States and globally. Furthermore, the company facilitates direct equipment rentals to patients. Founded in 2001, Inogen, Inc. is headquartered in Goleta, California.
6IO Company Deck
6IO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflects a company in transition: solid top-line growth driven by international expansion, strong unit volume gains, new product launches with encouraging early clinical and commercial signals, and a healthy balance sheet. Offsetting these positives are meaningful near-term headwinds in the U.S. market (declining direct and rental sales), higher operating losses due to accelerated R&D and commercial investments, and reliance on a FX tailwind. Management reaffirmed full-year guidance and expects EBITDA improvement, but several financial metrics remain under pressure in the near term.View all DE:6IO earnings summaries6IO Stock 12 Month Forecast
Average Price Target
€10.53
▲(80.04% Upside)
Technical Analysis
Options Prices
Currently, No data available
---